SYRS News and Press, Syros Pharmaceuticals Inc. From 05/03/23

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its firs...

2023-04-06 16:23:10 ET Syros Pharmaceuticals ( NASDAQ: SYRS ) on Thursday disclosed in an SEC filing a prospectus for a proposed mixed shelf offering to raise $250 million. The company expects to offer debt securities, common stock, preferred stock, units, and warrants under t...

2023-03-13 04:02:42 ET In wake of the bank's collapse with turmoil surrounding Silicon Valley Bank, several smaller pharma, biotech companies and health care equipment have come out and said they have exposure to FDIC-shuttered Silicon Valley Bank ( SIVB ). Among the biotec...

Syros Pharmaceuticals, Inc. (SYRS) Q4 2022 Earnings Conference Call March 02, 2023 08:30 AM ET Company Participants Karen Hunady - Director-Investor Relations & Corporate Communications Nancy Simonian - Chief Executive Officer David Roth - Chief Medical Officer ...

Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q4 GAAP EPS of -$0.17 beats by $1.13 . Cash, cash equivalents and marketable securities as of December 31, 2022 were $202.3 million, as compared with $143.4 million on December 31, 2021. Based on its current plans, Syro...

-- Commenced randomized portion of SELECT-AML-1 trial, with initial data expected in 4Q 2023 -- -- Received FDA Fast Track designation for tamibarotene for the treatment of HR-MDS -- -- On-track to complete enrollment in SELECT-MDS-1 trial in 4Q 2023, with pivotal data expecte...

Gainers: Okta ( OKTA ) +13% . Kezar Life Sciences ( KZR ) +7% . Esperion Therapeutics. ( ESPR ) +6% . Syros Pharmaceuticals ( SYRS ) +5% . ImmunityBio ( IBRX ) +5% . Losers: Funko ( FNKO ) -27% . ZimVie  ( ZIMV ...

Syros Pharmaceuticals ( NASDAQ: SYRS ) is scheduled to announce Q4 earnings results on Thursday, March 2nd, before market open. The consensus EPS Estimate is -$1.36 (-257.9% Y/Y) and the consensus Revenue Estimate is $3.85M (-95.1% Y/Y). Over the last 2 years, SYRS has beate...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its four...

Summary Final results from pivotal study SELECT-MDS-1, using Tamibarotene for the treatment of patients with newly diagnosed high-risk MDS that have RARA gene overexpression, expected Q3 of 2024. The global myelodysplastic syndrome market is expected to reach $5.6 billion by 2032; 50% o...